Influenza vaccine effectiveness against influenza-associated hospitalizations and emergency department or urgent care encounters among children and adults - United States, 2024-25 season
DeCuir, J.; Reeves, E. L.; Weber, Z. A.; Yang, D.-H.; Irving, S. A.; Tartof, S. Y.; Klein, N. P.; Grannis, S. J.; Ong, T. C.; Ball, S. W.; DeSilva, M. B.; Dascomb, K.; Naleway, A. L.; Koppolu, P.; Salas, S. B.; Sy, L. S.; Lewin, B.; Contreras, R.; Zerbo, O.; Hansen, J. R.; Block, L.; Jacobson, K. B.; Dixon, B. E.; Rogerson, C.; Duszynski, T.; Fadel, W. F.; Barron, M. A.; Mayer, D.; Chavez, C.; Yates, A.; Kirshner, L.; McEvoy, C. E.; Akinsete, O. O.; Essien, I. J.; Sheffield, T.; Bride, D.; Arndorfer, J.; Van Otterloo, J.; Natarajan, K.; Ray, C. S.; Payne, A. B.; Adams, K.; Flannery, B.; Garg,
Show abstract
BackgroundThe 2024-25 influenza season was the most severe in the United States (US) since 2017-18, with co-circulation of both influenza A virus subtypes (H1N1 and H3N2). Influenza vaccine effectiveness (VE) has varied by season, setting, and patient characteristics. MethodsUsing electronic healthcare encounter data from eight US states, we evaluated influenza vaccine effectiveness (VE) against influenza-associated hospitalizations and emergency department or urgent care (ED/UC) encounters from October 2024-April 2025 among children aged 6 months-17 years and adults aged [≥]18 years. Using a test-negative, case-control design, we compared the odds of influenza vaccination between acute respiratory illness (ARI) encounters with a positive (cases) versus negative (controls) test for influenza by molecular assay, adjusting for confounders. ResultsAnalyses included 108,618 encounters (5,764 hospitalizations and 102,854 ED/UC encounters) among children and 309,483 encounters (76,072 hospitalizations and 233,411 ED/UC encounters) among adults. Among children across care settings, 17.0% (6,097/35,765) of cases versus 29.4% (21,449/72,853) of controls were vaccinated. Among adults, 28.2% (21,832/77,477) of cases versus 44.2% (102,560/232,006) of controls were vaccinated. VE was 51% (95% confidence interval [95% CI]: 41-60%) against influenza-associated hospitalizations and 54% (95% CI: 52-55%) against influenza-associated ED/UC encounters among children. VE was 43% (95% CI: 41-46%) against influenza-associated hospitalizations and 49% (95% CI: 47-50%) against influenza-associated ED/UC encounters among adults. ConclusionsInfluenza vaccination provided protection against influenza-associated hospitalizations and ED/UC encounters among children and adults in the US during the severe 2024-25 influenza season. These findings support influenza vaccination as an important tool to reduce influenza-associated disease. Brief SummaryDuring the 2024-25 influenza season, influenza vaccination provided protection against influenza-associated hospitalizations (43-51%) and emergency department or urgent care encounters (49-54%) among children and adults in the United States.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Vaccine Effectiveness against COVID-19 among Symptomatic Persons Aged ≥12 Years with Reported Contact with COVID-19 Cases, February – September 2021 94%
- Increased Influenza Severity in Children in the Wake of SARS-CoV-2 94%
- Prior SARS-CoV-2 Infection and COVID-19 Vaccine Effectiveness against Outpatient Illness during Widespread Circulation of SARS-CoV-2 Omicron Variant, US Flu VE Network 94%
Similar papers in this journal
- Safety Monitoring of Health Outcomes following Influenza Vaccination during the 2023-2024 Season among U.S. Medicare Beneficiaries Aged 65 Years and Older 95%
- Receipt of COVID-19 and seasonal influenza vaccines in California (USA) during the 2021-2022 influenza season 95%
- Agreement between state registry, health record, and self-report of influenza vaccination 95%
Similar papers in this journal
- Effectiveness of Influenza Vaccines in the HIVE household cohort over 8 years: is there evidence of indirect protection? 95%
- The Nicaraguan Pediatric Influenza Cohort Study, 2011-2019: influenza incidence, seasonality, and transmission 94%
- Effectiveness of COVID-19 vaccines against hospitalization and death in Canada: A multiprovincial test-negative design study 93%
Similar papers in this journal
- Effectiveness of the BNT162b vaccine fourth dose in reducing SARS-CoV-2 infection among healthcare workers in Israel, a multi-center cohort study 91%
- Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis 91%
- Children with SARS-CoV-2 in the National COVID Cohort Collaborative (N3C) 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.